Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTRN12612000774820Phase 2Terminated
Phase 2, randomised trial in rheumatoid arthritis (RA) comparing MK-8457 plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoints: ACR20 response at Week 12 and Safety and tolerability over 12 weeks. Started Jan 2013; status: terminated.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ACTRN12612000774820.